Premium
Evidence for nonrenal synthesis of 1,25‐dihydroxyvitamin d in patients with inflammatory arthritis
Author(s) -
Mawer Barbara E.,
Hayes Michael E.,
Still Pamela E.,
Davies Michael,
Lumb Geoffrey A.,
Palit Jayanta,
Holt Lennox P.J.
Publication year - 1991
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650060711
Subject(s) - rheumatoid arthritis , metabolite , medicine , endocrinology , synovial fluid , arthritis , in vivo , hydroxylation , chemistry , pathology , enzyme , biochemistry , biology , alternative medicine , microbiology and biotechnology , osteoarthritis
The extrarenal synthesis of 1,25‐dihydroxyvitamin D [1,25‐(OH) 2 D] is a characteristic of activated macrophages and has been demonstrated to occur in vitro in synovial fluid macrophages from patients with inflammatory arthritis. To examine whether such synthesis occurs in vivo, 19 patients with rheumatoid arthritis, 5 patient controls, and 5 healthy controls received a challenge oral dose of 250 μg 25‐hydroxyvitamin D 3 (25‐OHD 3 ) and the serum 1,25‐(OH) 2 D 3 response was measured. The median rise in serum 1,25‐(OH) 2 D 3 was significantly greater (22 pg/ml) in the rheumatoid patients compared to either of the control groups (8 pg/ ml), although the increase in precursor 25‐OHD 3 was similar in all groups. The serum 1,25‐(OH) 2 D concentration did not rise above the normal upper limit in any of the control subjects but exceeded the normal range in 8 of the rheumatoid patients. Extrarenal 1,25‐(OH) 2 D synthesis is substrate dependent, unlike renal 1α‐hydroxylation, which is homeostatically controlled. Excessive 1,25‐(OH) 2 D 3 synthesis in the rheumatoid group on raising the 25‐OHD 3 concentration is indicative of nonrenal production of the hormonal metabolite. Further evidence for substrate‐dependent extrarenal synthesis came from measurements of 25‐OHD and 1,25‐(OH) 2 D in paired serum and synovial fluid samples from 19 patients with inflammatory arthritis, including 15 with rheumatoid arthritis. Synovial fluid 1,25‐(OH) 2 D was usually present at a lower concentration than serum 1,25‐(OH) 2 D, with which it was strongly correlated (Kendall's R = 0.46, P < 0.001). Synovial fluid 1,25‐(OH) 2 D was also correlated with synovial fluid 25‐OHD ( R = 0.55, P < 0.001), but serum 1,25‐(OH) 2 D and 25‐OHD were not related. At high synovial fluid 25‐OHD concentrations the 1,25‐(OH) 2 D level in synovial fluid exceeded that in serum, suggesting local synthesis of 1,25‐(OH) 2 D within the synovium. Distribution of vitamin D metabolites between serum and synovial fluid could not be explained by the relevant concentrations of vitamin D binding protein. Together these results provide strong evidence for nonrenal synthesis of 1,25‐(OH) 2 D in patients with inflammatory arthritis. The extent of synovial synthesis of 1,25‐(OH) 2 D may be governed both by the severity of the inflammatory disease and by drug treatment. Such synthesis may be significant in the immunoregulatory system in the affected joint and may prove to have relevance to the development of periarticular osteoporosis in rheumatoid arthritis.